Comparative Pharmacology
Head-to-head clinical analysis: IQUIX versus OFLOXACIN.
Head-to-head clinical analysis: IQUIX versus OFLOXACIN.
IQUIX vs OFLOXACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DNA gyrase inhibitor; topoisomerase IV inhibitor; bactericidal against Gram-positive and Gram-negative bacteria by blocking DNA replication.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
1-2 drops of 0.5% solution in affected eye(s) every 2 hours while awake for 2 days, then 1-2 drops every 4 hours while awake for up to 5 days total.
400 mg orally or intravenously every 12 hours for 7-14 days; for uncomplicated gonorrhea, 400 mg as a single oral dose.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. This short half-life supports twice-daily dosing in clinical practice (for ophthalmic suspension).
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOfloxacin + Digoxin
"Ofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLevofloxacin + Digoxin
"Levofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 4-8 hours in adults with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <20 mL/min).
Primarily renal excretion of unchanged drug (approximately 70-80%). A smaller fraction is excreted as metabolites via the kidneys. Biliary/fecal elimination accounts for less than 10% of the dose.
Approximately 70-90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 4-8% is excreted in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic